Rifamycin treatment of tuberculosis in a patient receiving atenolol: Less interaction with rifabutin than with rifampin

被引:7
作者
Goldberg, SV
Hanson, D
Peloquin, CA
机构
[1] Publ Hlth Seattle & King Cty, TB Control Program, Seattle, WA 98104 USA
[2] Virginia Mason Med Ctr, Seattle, WA 98101 USA
[3] Natl Jewish Med & Res Ctr, Pharmacokinet Lab, Denver, CO USA
关键词
D O I
10.1086/376648
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
引用
收藏
页码:607 / 608
页数:2
相关论文
共 3 条
[1]  
[Anonymous], 2003, AM J RESP CRIT CARE, V167, P603
[2]   Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis [J].
Burman, WJ ;
Gallicano, K ;
Peloquin, C .
CLINICAL INFECTIOUS DISEASES, 1999, 28 (03) :419-429
[3]   A regimen containing rifabutin for the treatment of tuberculosis in patients intolerant to rifampin [J].
Tattevin, P ;
Revest, M ;
Dupont, M ;
Arvieux, CD ;
Michelet, C .
CLINICAL INFECTIOUS DISEASES, 2003, 36 (01) :127-128